Bank of New York Mellon Corp Has $976,000 Stake in Kodiak Sciences Inc. (NASDAQ:KOD)

Bank of New York Mellon Corp grew its position in Kodiak Sciences Inc. (NASDAQ:KOD) by 5.3% during the fourth quarter, HoldingsChannel reports. The firm owned 98,102 shares of the company’s stock after buying an additional 4,927 shares during the period. Bank of New York Mellon Corp’s holdings in Kodiak Sciences were worth $976,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. SG Americas Securities LLC lifted its stake in Kodiak Sciences by 61.4% in the fourth quarter. SG Americas Securities LLC now owns 20,684 shares of the company’s stock valued at $206,000 after buying an additional 7,871 shares during the period. Geode Capital Management LLC increased its stake in shares of Kodiak Sciences by 1.7% in the 3rd quarter. Geode Capital Management LLC now owns 768,740 shares of the company’s stock valued at $2,007,000 after acquiring an additional 12,783 shares in the last quarter. State Street Corp lifted its position in shares of Kodiak Sciences by 1.8% during the 3rd quarter. State Street Corp now owns 816,634 shares of the company’s stock valued at $2,131,000 after acquiring an additional 14,711 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Kodiak Sciences by 220.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company’s stock valued at $117,000 after acquiring an additional 30,735 shares during the period. Finally, Barclays PLC boosted its stake in Kodiak Sciences by 65.5% during the third quarter. Barclays PLC now owns 79,658 shares of the company’s stock worth $208,000 after acquiring an additional 31,527 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group raised shares of Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research note on Monday, December 9th.

Kodiak Sciences Stock Down 9.1 %

NASDAQ KOD opened at $3.20 on Wednesday. Kodiak Sciences Inc. has a 52 week low of $2.19 and a 52 week high of $11.60. The business has a 50 day moving average price of $5.15 and a 200-day moving average price of $5.43. The company has a market cap of $168.40 million, a price-to-earnings ratio of -0.88 and a beta of 2.26.

Kodiak Sciences Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.